Results 241 to 250 of about 40,704 (273)
Some of the next articles are maybe not open access.
CYP2C19 gene polymorphism in Ningxia
Pharmacological Reports, 2023Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci ...
Zhen Yang +8 more
openaire +2 more sources
Mycoses (Berlin), 2021
Voriconazole primary metabolism is catalysed by CYP2C19. A large variability of trough concentrations in patients with invasive fungal infection treated with voriconazole has been observed in clinical practice.
Ying Zhang +8 more
semanticscholar +1 more source
Voriconazole primary metabolism is catalysed by CYP2C19. A large variability of trough concentrations in patients with invasive fungal infection treated with voriconazole has been observed in clinical practice.
Ying Zhang +8 more
semanticscholar +1 more source
The Journal of Pharmacology and Experimental Therapeutics, 1998
A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations.
G C, Ibeanu +7 more
openaire +2 more sources
A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations.
G C, Ibeanu +7 more
openaire +2 more sources
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*
Clinical Pharmacology & Therapeutics, 1995The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8). All were extensive metabolizers of sparteine.
Kirsten Vistisen +14 more
openaire +3 more sources
Journal of Clinical Pharmacy and Therapeutics, 2010
CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.A multiplex pyrosequencing method to simultaneously ...
Kim Kr, K.A. Kim, W K Song, Joori Park
openaire +3 more sources
CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.A multiplex pyrosequencing method to simultaneously ...
Kim Kr, K.A. Kim, W K Song, Joori Park
openaire +3 more sources
Clopidogrel, CYP2C19, and a Black Box
The Journal of Clinical Pharmacology, 2013AbstractIt has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel. This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD‐Supersomes™). If clopidogrel were primarily a CYP2C19 substrate, a drug/drug interaction with CYP2C19 inhibitors, such as proton pump
Neville F. Ford, Dirk Taubert
openaire +3 more sources
Molecular Biology Reports, 2011
To relate the pharmacokinetics of orally administered lansoprazole in healthy adult Jordanian men with CYP2C19 polymorphisms and to determine the percentage of CYP2C19 polymorphism in Jordanian population and the allelic frequency of CYP2C19*2 and CYP2C19*3.
Tawfiq Arafat +3 more
openaire +3 more sources
To relate the pharmacokinetics of orally administered lansoprazole in healthy adult Jordanian men with CYP2C19 polymorphisms and to determine the percentage of CYP2C19 polymorphism in Jordanian population and the allelic frequency of CYP2C19*2 and CYP2C19*3.
Tawfiq Arafat +3 more
openaire +3 more sources
The Journal of Clinical Pharmacology, 2009
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial.
Yalin Li +12 more
openaire +3 more sources
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial.
Yalin Li +12 more
openaire +3 more sources
Xenobiotica, 2010
The objective of this study was to investigate the interaction between glycyrrhizin and omeprazole and observe the effects of glycyrrhizin on CYP2C19 and CYP3A4 activities in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen healthy subjects (six CYP2C19*1/*1, five CYP2C19*1/*2, one CYP2C19*1/*3, five CYP2C19*2/*2 and one ...
L.-L. Dai +9 more
openaire +2 more sources
The objective of this study was to investigate the interaction between glycyrrhizin and omeprazole and observe the effects of glycyrrhizin on CYP2C19 and CYP3A4 activities in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen healthy subjects (six CYP2C19*1/*1, five CYP2C19*1/*2, one CYP2C19*1/*3, five CYP2C19*2/*2 and one ...
L.-L. Dai +9 more
openaire +2 more sources